Impel NeuroPharma Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Impel NeuroPharma's estimated annual revenue is currently $17.1M per year.
- Impel NeuroPharma received $67.5M in venture funding in December 2018.
- Impel NeuroPharma's estimated revenue per employee is $251,000
- Impel NeuroPharma's total funding is $108M.
- Impel NeuroPharma has 68 Employees.
- Impel NeuroPharma grew their employee count by 26% last year.
- Impel NeuroPharma currently has 2 job openings.
|Kelsey Satterly||Director, Life Sciences|
|Lynn Gold||Senior Vice President Regulatory Affairs|
|John Hoekman||Co-Founder/Chief Scientific Officer|
|Ben Mansour||Sr. Manager , Operations Gmp|
|Sutapa Ray||Medical Communications Manager, Medical Affairs|
|Scott Youmans||Senior Vice President, Engineering|
|Christopher Fuller||Director Of Engineering|
|Beatrix Taylor||Director of Regulatory Affairs|
|Jon Congleton||President and CEO|
|Karena Teves||Program Manager|
What Is Impel NeuroPharma?
Impel NeuroPharma, Inc., is a privately-held, Seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Impel's products are based on a novel nasal drug delivery platform, the POD device, that administers drug to the upper nasal cavity in a consistent and predictable manner. Impel NeuroPharma is currently investigating INP104 (POD DHE) for acute migraine headache, INP103 (POD levodopa) for Parkinson's Disease, INP105 (POD olanzapine) for agitation in schizophrenia and bipolar disorders as well as INP102 (POD insulin) for Alzheimer's disease in an NIH funded trial. Impel NeuroPharma's proprietary POD device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com.keywords:Biotechnology,Cleantech,Healthcare,Medical Devices,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Young Dental Ca...||$11.8M||47||15%||N/A|
|Kestra Medical ...||$14.6M||58||38%||N/A|
Impel NeuroPharma News
SEATTLE, Sept. 5, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and ...
3, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of ...
Impel NeuroPharma announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal ...
Impel NeuroPharma Funding
|2015-10-15||$12.0M||B||3M New Ventures||Article|
Impel NeuroPharma Executive Hires
|2018-07-17||Lynn Gold||SVP Regulatory Affairs||Article|
|2018-11-08||Ellen Lubman||Chief Business Officer||Article|
|2019-02-20||Jennifer Berman||Vice President of Marketing||Article|